Patients with diabetes were more likely to receive drugs acting on the renin-angiotensin system (RAS blockade), either an ACE-inhibitor or an angiotensin receptor blocker, either at baseline or at some time during the study. This evidence concerns the gene REN and diabetes mellitus.